Ask the experts: Three key questions on mCRC

Harpreet Wasan is a Professor in Medical Oncology and leads the gastrointestinal clinical research program at Hammersmith Hospital, Imperial College London and is current Lead for Cancer for The N.W. London NIHR Research network. His research interests cover CRC, Biliary, Pancreatic Cancer & CUP and has led and participated in trials that have led to global new standards of care with interests in designing and implementing novel paradigm & interventional trials (including non-drug interventions) in GI cancer.

Dr Naureen Starling is a Consultant Medical Oncologist at The Royal Marsden specialising in treatment of gastrointestinal (GI) cancers, Associate Director of Clinical Research for the Royal Marsden, and is a Reader within the Division of Clinical Studies at the Institute of Cancer Research.

Her research interests are focused on earlier phase clinical trials, novel therapeutics/technologies, and the delivery of individualised medicine to patients with GI cancers. She is the principal investigator on numerous international clinical trials of novel drugs in oesophago-gastric, pancreatic, and colorectal cancer, a member of several multi-centre clinical trial steering and safety review committees and has been a lead or co-applicant on several successful peer-reviewed research grant applications including clinical research to bring liquid biopsies based on ctDNA to the clinic.

She serves on the UK NCRI colorectal and oesophago-gastric sub-groups and has acted as a clinical expert in oesophago-gastric and colorectal cancer for NICE, is a trustee for PCUK, has been a faculty member at ESMO and ASCO meetings, and is the Precision Therapeutics Theme Lead for RM/ICR NIHR BRC.

Dr Paul Ross is a Consultant Medical Oncologist at Guy’s & St Thomas’ and King’s College Hospitals. He specialises in HPB and colorectal cancers. He has served on national groups including: NCRI Upper GI Cancers Clinical Studies group, its hepato-biliary sub-group; NCRI CRC adjuvant & advanced disease group; NHSEs Chemotherapy Clinical Reference group; Association of Cancer Physicians. His research interests are focussed around pharmacogenomics, interventional oncology and clinical trials. Paul trained at the Royal Marsden Hospital and Institute of Cancer Research. His Research was awarded the Association of Cancer Physicians McElwain prize and an American Society of Clinical Oncology Merit award.